Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II long-term safety and efficacy of Teverelix LA in advanced prostate cancer (follow-on to ARD-0301-004)
2007-004349-13Phase 2Completed
- Sponsor
- Ardana
- Start
- Aug 2007
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teverelix in prostate cancer (PCa), sponsored by Ardana. Primary endpoints: Maintenance of castration-level testosterone until Week 28, Long-term safety and tolerability of Teverelix LA and 1 more. Started Aug 2007; status: completed.
02
Drugs
teverelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2007-004349-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004349-13.